Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) used an Oct. 21, 2026 investor presentation to reaffirm that topline results from its APPROACH Phase 3 study of HLP003 as an adjunctive treatment for major depressive disorder remain on track for the fourth quarter of 2026, a timeline that matters because it sits at the front of the company's path toward a New Drug Application expected in 2028.
The company, the commercial operating name of Cybin Inc., said enrollment of 223 participants in APPROACH was completed in July, and enrollment continues in EMBRACE, the second pivotal Phase 3 study. HLP003, a proprietary novel serotonergic agonist designed to activate serotonin pathways believed to promote neuroplasticity, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. That designation is significant for readers because it signals regulatory recognition of the drug's potential in a condition where the company says unmet need remains large.
Separately, Helus Pharma outlined plans to initiate a Phase 2 study of HLP004 as a potential monotherapy for generalized anxiety disorder in the first quarter of 2027. The randomized, double-blind, placebo-controlled study is expected to enroll approximately 144 adults to evaluate two 30 mg administrations of HLP004 against placebo, with primary and key secondary efficacy assessments at weeks six and 12, respectively.
The dual-program update is the kind of disclosure investors in clinical-stage biotechnology weigh carefully, since trial readouts and regulatory submissions are the events that typically shape valuations before any commercialization. Helus Pharma said the advancement of both programs represents an important period as it works toward regulatory approval and potential commercialization. For patients and clinicians, the significance lies in the company's stated aim of providing durable improvements in mental health through NSAs, or novel serotonergic agonists, a class it says is intended to address depression, anxiety and other conditions.
Full details of the presentation were released by Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), with the full press release available at https://ibn.fm/ahWlS. The company maintains a corporate site at www.helus.com. The update was distributed through PsychedelicNewsWire, one of the brands in the Dynamic Brand Portfolio at IBN, which delivers wire solutions through InvestorWire and offers corporate communications solutions.
Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland. With HLP003 in Phase 3 and HLP004 poised to enter Phase 2, the coming quarters will test whether the company can convert its clinical momentum into regulatory progress, a question that carries weight for investors and for people living with depression and anxiety.
